➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Johnson and Johnson
McKesson
McKinsey
Express Scripts

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

MYCOBUTIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Mycobutin patents expire, and when can generic versions of Mycobutin launch?

Mycobutin is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in MYCOBUTIN is rifabutin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the rifabutin profile page.

US ANDA Litigation and Generic Entry Outlook for Mycobutin

A generic version of MYCOBUTIN was approved as rifabutin by LUPIN LTD on February 24th, 2014.

  Start Trial

Drug patent expirations by year for MYCOBUTIN
Drug Prices for MYCOBUTIN

See drug prices for MYCOBUTIN

Recent Clinical Trials for MYCOBUTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of BariPhase 3
Centre for Digestive Diseases, AustraliaPhase 2
Cadrock Pty. Ltd.Phase 2

See all MYCOBUTIN clinical trials

Pharmacology for MYCOBUTIN

US Patents and Regulatory Information for MYCOBUTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn MYCOBUTIN rifabutin CAPSULE;ORAL 050689-001 Dec 23, 1992 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.